News | May 17, 2022
BDR Pharma receives Rs. 685 crore of PE investment
Multiples is the first private equity (PE) investor in the company
Multiples is the first private equity (PE) investor in the company
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
The plant is scheduled to come on stream in September 2024
Christian brings a unique level of experience and expertise from a 20-year career at BASF across multiple territories and businesses
The scope of supply includes the skid-mounted plant as well as on-site installation and commissioning support
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
Company expects strong organic growth in sales, EBITDA in 2022
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Subscribe To Our Newsletter & Stay Updated
